• Please log in or register to access this feature.
You have full text access to this OnlineOpen article

Platelet-delivered factor VIII provides limited resistance to anti-factor VIII inhibitors

  1. J. GEWIRTZ1,
  2. M. A. THORNTON2,
  3. L. RAUOVA1,
  4. M. PONCZ1,3

Article first published online: 28 JUN 2008

DOI: 10.1111/j.1538-7836.2008.02992.x

Issue

Journal of Thrombosis and Haemostasis

Journal of Thrombosis and Haemostasis

Volume 6, Issue 7, pages 1160–1166, July 2008

Additional Information

How to Cite

GEWIRTZ, J., THORNTON, M. A., RAUOVA, L. and PONCZ, M. (2008), Platelet-delivered factor VIII provides limited resistance to anti-factor VIII inhibitors. Journal of Thrombosis and Haemostasis, 6: 1160–1166. doi: 10.1111/j.1538-7836.2008.02992.x

Author Information

  1. 1

    Division of Hematology, Children’s Hospital of Philadelphia, Philadelphia, PA

  2. 2

    Department of Biology, Florida A&M University, Tallahassee, FL

  3. 3

    Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

*Mortimer Poncz, Children’s Hospital of Philadelphia, 3615 Civic Center Blvd, ARC, Rm. 317, Philadelphia, PA 190104, USA. Tel.: +1 215 590 3574; fax: +1 267 426 5476. E-mail: poncz@email.chop.edu

Publication History

  1. Issue published online: 28 JUN 2008
  2. Article first published online: 28 JUN 2008
  3. Received 17 January 2008, accepted 7 April 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (292K)

References

  • 1
    Castaldo G, D’Argenio V, Nardiello P, Zarrilli F, Sanna V, Rocino A, Coppola A, Di Minno G, Salvatore F. Haemophilia A: molecular insights. Clin Chem Lab Med 2007; 45: 450–61.
  • 2
    Ponder KP. Gene therapy for hemophilia. Curr Opin Hematol 2006; 13: 301–7.
  • 3
    Yarovoi H, Kufrin D, Eslin DE, Zhu H, Wilcox DA, Camire R, Fakharzadeh SS, Kowalska MA, Montgomery RR, Poncz M. Factor VIII ectopically expressed in platelets. Efficacy in hemophilia A treatment. Blood 2003; 102: 4006–13.
  • 4
    Yarovoi H, Nurden AT, Montgomery RR, Nurden P, Poncz M. Intracellular interaction of Von Willebrand Factor and Factor VIII depends on cellular context: lessons from platelet expressed Factor VIII. Blood 2005; 105: 4674–6.
  • 5
    Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 1995; 10: 119–21.
  • 6
    Shi Q, Wilcox DA, Fahs SA, Weiler H, Wells CW, Cooley BC, Desai D, Morateck PA, Gorski J, Montgomery RR. Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies. J Clin Invest 2006; 116: 1974–82.
  • 7
    High KA. The leak stops here: platelets as delivery vehicles for coagulation factors. J Clin Invest 2006; 116: 1840–2.
  • 8
    Andrews N. Putting platelets to work to circumvent hemophilia inhibitors. Hematologist 2006; 3: 8.
  • 9
    Dasgupta S, Navarrete AM, Delignat S, Wootla B, Andre S, Nagaraja V, Lacroix-Desmazes S, Kaveri SV. Immune response against therapeutic factor VIII in hemophilia A patients – a survey of probable risk factors. Immunol Lett 2007; 110: 23–8.
  • 10
    Mathew P. Current opinion on inhibitor treatment options. Semin Hematol 2006; 43: S8–13.
  • 11
    Fay WP, Parker AC, Ansari MN, Zheng X, Ginsburg D. Vitronectin inhibits the thrombotic response to arterial injury in mice. Blood 1999; 93: 1825–30.
  • 12
    Pittman DD, Alderman EM, Tomkinson KN, Wang JH, Giles AR, Kaufman RJ. Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII. Blood 1993; 81: 2925–35.
  • 13
    Hashimoto Y, Ware J. Identification of essential GATA and Ets binding motifs within the promoter of the platelet glycoprotein Ib alpha gene. J Biol Chem 1995; 270: 24532–9.
  • 14
    Fujita H, Hashimoto Y, Russell S, Zieger B, Ware J. In vivo expression of murine platelet glycoprotein Ibalpha. Blood 1998; 92: 488–95.
  • 15
    Scandella D, Gilbert GE, Shima M, Nakai H, Eagleson C, Felch M, Prescott R, Rajalakshmi KJ, Hoyer LW, Saenko E. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood 1995; 86: 1811–9.
  • 16
    Villard S, Piquer D, Raut S, Leonetti JP, Saint-Remy JM, Granier C. Low molecular weight peptides restore the procoagulant activity of factor VIII in the presence of the potent inhibitor antibody ESH8. J Biol Chem 2002; 277: 27232–9.
  • 17
    Verbruggen B, Novakova I, Wessels H, Boezeman J, Van Den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247–51.
  • 18
    Saenko EL, Shima M, Gilbert GE, Scandella D. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition. J Biol Chem 1996; 271: 27424–31.
  • 19
    Saenko EL, Shima M, Rajalakshmi KJ, Scandella D. A role for the C2 domain of factor VIII in binding to von Willebrand factor. J Biol Chem 1994; 269: 11601–5.
  • 20
    Hsu TC, Pratt KP, Thompson AR. The factor VIII C1 domain contributes to platelet binding. Blood 2008; 111: 200–8.
  • 21
    Handagama P, Rappolee DA, Werb Z, Levin J, Bainton DF. Platelet alpha-granule fibrinogen, albumin, and immunoglobulin G are not synthesized by rat and mouse megakaryocytes. J Clin Invest 1990; 86: 1364–8.
  • 22
    George JN, Saucerman S, Levine SP, Knieriem LK, Bainton DF. Immunoglobulin G is a platelet alpha granule-secreted protein. J Clin Invest 1985; 76: 2020–5.
  • 23
    Millward TA, Heitzmann M, Bill K, Langle U, Schumacher P, Forrer K. Effect of constant and variable domain glycosylation on pharmacokinetics of therapeutic antibodies in mice. Biologicals 2008; 36: 41–7.
  • 24
    Kufrin D, Eslin DE, Bdeir K, Murciano J-C, Kuo A, Kowalska MA, Degen JL, Sachais BS, Cines DB, Poncz M. Anti-thrombotic thrombocytes. Ectopic expression of urokinase-type plasminogen activator in platelets. Blood 2003; 102: 926–33.
  • 25
    Mordenti J, Osaka G, Garcia K, Thomsen K, Licko V, Meng G. Pharmacokinetics and interspecies scaling of recombinant human factor VIII. Toxicol Appl Pharmacol 1996; 136: 75–8.
  • 26
    Shi Q, Fahs SA, Wilcox DA, Kuether EL, Weiler H, Montgomery RR. In the presence of pre-existing factor VIII (FVIII) immunity, hematopoietic stem cells (HSC) that are genetically modified to express FVIII in platelets were successfully transplanted into hemophilic mice under myeloablative and various non-myeloablative conditions. Blood 2007; 110: 236a.
  • 27
    Italiano J, Richardson JL, Folkman J, Klement G. Blood platelets organize pro- and anti-angiogenic factors into separate, distinct alpha granules: implications for the regulation of angiogenesis. Blood 2006; 108: 120a.
  • 28
    Olson PS, Ljungqvist U, Bergentz SE. Analysis of platelet, red cell and fibrin content in experimental arterial and venous thrombi. Thromb Res 1974; 5: 1–19.
  • 29
    Furie BC, Furie B. Tissue factor pathway vs. collagen pathway for in vivo platelet activation. Blood Cells Mol Dis 2006; 36: 135–8.
  • 30
    Spira J, Plyushch OP, Andreeva TA, Andreev Y. Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes. Blood 2006; 108: 3668–73.
View Full Article (HTML) Get PDF (292K)